Main > > >THYROID CANCER. *

---

Diagnostics: Genomic Sequencing Classi-fier (GSC) & Expression Atlas provide physicians with a comprehensive solution for a complex landscape in thyroid cancer diagnosis and individualization of care. The combined offering enables physicians to answer multiple clinical questions for their thyroid patients using a single, minimally invasive Fine Needle Aspiration (FNA) sample.
The GSC Test was developed with RNA whole-transcriptome sequencing and machine learning to identify benign thyroid nodules among those deemed indeterminate by cytopathology so that these patients may avoid unnecessary surgery.
USA Launch Date: 2018. 05.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.13.




Diagnostics: Windows-based CAD (Computer
Assisted Detection) Device intended to assist the medical professionals in analyzing thyroid "ultrasound" images, acquired from FDA-cleared ultrasound systems, with user‐selected regions of interest (ROI). After the initial review of the ultrasound images by the physi- cians, the device further provides detailed information with quantification and visualization of sonographic charac-teristics of thyroid nodules. The device is intended for use on ultrasound images of discrete thyroid nodules larger than 1cm, for which a biopsy recommendation is required
CN; EU & TW Approval Date: ?
USA Approval Date: 2018. 08.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.20.




Prevention: Liquid KI Oral Solution.
for Nuclear Emergency Management.
in event of radiation exposure.
USA Approval Date: 2016. 05.17
(*) Company: Mission Pharmacal Co.
UpDate: 2018. 12.19.




Treat.: Cabozantinib Capsules.
(Medullary; Metastatic).
USA Approval Date: 2012. 11.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.20.




Treat.: Dabrafenib Capsules+Trametinib
Tablets.
(Anaplastic METASTATIC with BRAF V600E Mutation).
USA Approval Date: 2018. 05.04.
(*) Company; Patents; PR Web-Site &
TradeMark Available on Request.
UpDate: 2018. 11.03.




Treat.: Lenvatinib Capsules.
CA; EU; JP; KR Approval
USA Approval Date: 2015. 02.13.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.20.




Treat.: LevoThyroxine Na Oral Liquid.
USA Approval Date: 2017. 02.15.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 12.19.




Treat.: NaI I-131.
USA Approval Date: 2020. 02.10.
(*) Company: Intl. Isotopes.
UpDate: 2020. 02.11.




Treat.: Pralsetinib Capsules.
(METASTATIC; RET Fusion+)
USA Approval Date: 2020. 12.01.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2021. 02.13.




Treat.: Selpercatinib Capsules.
(METASTATIC; RET Fusion+)
USA Approval Date: 2020. 05.08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.22.




Treat.: Thyrotropin Alfa for Inj.
USA Approval Date: 1998. 11.30.
(*) Company : Sanofi Genzyme.
TradeMark: Thyrogen
Web-Site : www.thyrogen.com
UpDate: 2018. 12.20.




Treat.: Vandetanib Tablets.
(Medullary; Metastatic)
USA Approval Date: 2011. 04.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 12.20.


>THYROID CANCER. *'s products
This section has no products